TICKERNERD
Menu
AUPHAUPHHealthcare · Biotechnology

AUPH Stock Forecast: Aurinia Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 13 Aug 2026
$15
−1.75% on the day

The 7 Wall Street analysts covering Aurinia Pharmaceuticals, Inc. hold a median 12-month price target of $17 — +12.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 95 of 100 as at 13 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$2.0B
Ticker Nerd rank
95 / 100
Median analyst target
$17
Analysts covering
7
Total return, dividends reinvested
1W
−5.9%
1M
−5.3%
YTD
−4.8%
1Y
+26.4%
From 52W high
−18.5%
From 52W low
+37.4%
$11
$19
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

AUPH stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Aurinia Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 13 Aug 2026
95 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
99
Quality
97
Volatility
96
Issuance
91
Growth
81
Momentum
79
Revisions
60
Size
36
Accruals
22

Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Accruals (22): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

The Ticker Nerd Read

Ranked 95 of 100, with earnings quality the deepest doubt.

As of August 10, 2026, our factor model ranks Aurinia Pharmaceuticals 95.4 of 100 across the roughly 4,600 US stocks we track. The Value family leads at 99.3 — the shares cost little relative to the profits behind them — with Quality at 96.6 and a share count shrinking under a 91.4 Debt/Equity reading. The deepest drag is Investment/Accruals at 21.9, driven by an earnings-quality score of 16.4, and the shares also sit at 36.0 on size because their market cap exceeds most names we track.

As of August 11, 2026, consensus EPS for the current year is $0.944, cut 1.7% over 90 days, and the matching Estimate Revisions factor sits at 59.9. The median analyst target is $17 against a last close of $15.47 on August 10, 2026, with four buy and three hold ratings among seven analysts.

The divide inside the price-earnings picture shows what a shift would look like. As of August 11, 2026 the trailing multiple is 6.9 and the forward multiple is 14.7, a gap resting on the December 2025 quarter's $210.8 million in reported net income versus $31.6 million to $34.4 million in the quarters on either side. A quarter that turns more of that reported profit into operating cash would repair the weak accruals rung; another gain recorded before it reaches cash would widen it.

As of 11 Aug 2026
Wall Street

AUPH stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AUPH, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$12$14$16$18$20Oct 25Jan 26Apr 26Jul 26AUPHHigh $20Median $17Low $15

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says7 analysts
4 Buy3 Hold0 Sell
Low $15Median $17High $20

The green dot is the last close — the median target sits +12.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
7 Aug 2026RBC CapitalMaintainsSector Perform$15 → $16
3 Dec 2025Leerink PartnersDowngradeMarket Perform—
3 Dec 2025Leerink PartnersDowngradeMarket Perform$15 → $16
7 Nov 2025JefferiesUpgradeBuy—
5 Nov 2025RBC CapitalDowngradeSector Perform—
1 Aug 2025RBC CapitalMaintainsOutperform—
30 July 2025HC Wainwright & Co.AssumesBuy$17
16 Sept 2024Cantor FitzgeraldReiteratesOverweight—
9 Sept 2024Cantor FitzgeraldReiteratesOverweight—
6 Sept 2024HC Wainwright & Co.ReiteratesBuy—
1 Mar 2024HC Wainwright & Co.ReiteratesBuy—
23 Feb 2024Cantor FitzgeraldMaintainsOverweight—
22 Feb 2024HC Wainwright & Co.MaintainsBuy—
16 Feb 2024RBC CapitalMaintainsOutperform—
22 Sept 2023HC Wainwright & Co.ReiteratesBuy—
7 Aug 2023HC Wainwright & Co.MaintainsBuy$14 → $15
7 Aug 2023HC Wainwright& Co.MaintainsBuy—
6 July 2023Cantor FitzgeraldReiteratesOverweight—
3 May 2023HC Wainwright & Co.ReiteratesBuy—
23 Feb 2023RBC CapitalReiteratesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AUPH appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

AUPH analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−1.7%
Analysts raising
0
Analysts cutting
1
Fundamentals

Aurinia Pharmaceuticals, Inc. (AUPH) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
6.8×

Cheaper than 64% of US stocks

Price / sales
6.6×

Cheaper than 20% of US stocks

Price / book
3.3×

Cheaper than 32% of US stocks

EV / EBITDA
9.3×

Cheaper than 41% of US stocks

Growth & margins
Revenue growth (YoY)
18.9%

Higher than 68% of US stocks

Earnings growth (YoY)
73.9%

Higher than 81% of US stocks

Gross margin
92.1%

Higher than 97% of US stocks

Operating margin
55.7%

Higher than 98% of US stocks

Net margin
100.8%

Higher than 99% of US stocks

Returns & dividend
Return on equity
66.1%

Higher than 94% of US stocks

Return on assets
15.5%

Higher than 97% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

AUPH vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
AUPHAurinia Pharmaceuticals, Inc.$2.0B
95
SEPNSepterna, Inc.$2.0B
91
VERAVera Therapeutics, Inc.$2.0B
24
KARDKardigan, Inc.$2.0B
0
AGIOAgios Pharmaceuticals, Inc.$2.0B
81
STOKStoke Therapeutics, Inc.$1.9B
54
NUVBNuvation Bio, Inc.$2.1B
66

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Aurinia Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AUPH news & analysis

Aurinia Pharmaceuticals Doubles Down On Its Pipeline

Seeking Alpha · 12 Aug 2026neutral

Aurinia Pharmaceuticals is advancing its pipeline, running the phase 4 PRESERVE trial in lupus nephritis testing combinations containing its drug Lupkynis, and developing aritinercept across four potential indications. However, Lupkynis could face potential challenges to its market exclusivity in the near future, and the company provides little clarity on timelines for further aritinercept updates.

Why it matters — AUPH watchers would care because this update addresses both the company's pipeline progress and potential risks to the market position of its key drug Lupkynis.

Aurinia Pharmaceuticals (AUPH) Surpasses Q2 Earnings Estimates

Zacks Investment Research · 6 Aug 2026positive

Aurinia Pharmaceuticals reported Q2 earnings of $0.28 per share, surpassing the Zacks Consensus Estimate of $0.19 per share and up from $0.16 per share a year ago.

Why it matters — The results indicate Aurinia's quarterly earnings came in well above analyst expectations and improved year over year.

Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress

Business Wire · 6 Aug 2026neutral

Aurinia Pharmaceuticals announced via Business Wire that it reported financial results for the three and six months ended June 30, 2026, and provided an update on recent business progress.

Why it matters — This release gives AUPH watchers an official look at the company's half-year financial performance and current business developments.

Top Healthcare Stocks Beyond The Market Rotation Averaging 128% Forward EPS Growth

Seeking Alpha · 24 July 2026neutral

Healthcare stocks have outperformed over the past month as investors rotate away from AI and other risk-on assets. Global fund managers increased healthcare holdings more than any other sector, per Bank of America's July survey, as defensive sectors tend to gain in volatile markets.

Why it matters — As a healthcare stock, AUPH could benefit from the broader sector rotation and increased fund manager interest in defensive healthcare positions during market uncertainty.

FAQ

Frequently asked questions about AUPH stock

What is the AUPH stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Aurinia Pharmaceuticals, Inc. have a median 12-month price target of $17, with estimates ranging from $15 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AUPH stock a buy right now?

Of the 7 analysts covering Aurinia Pharmaceuticals, Inc., 4 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Aurinia Pharmaceuticals, Inc. 95 out of 100 across roughly 4,600 US stocks as at 13 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AUPH?

As at 13 Aug 2026, Aurinia Pharmaceuticals, Inc. ranks 95 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).

Will AUPH stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +12.0% from the last close, and Ticker Nerd's factor model ranks Aurinia Pharmaceuticals, Inc. 95 out of 100 as at 13 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AUPH stock forecast for 2030?

No analyst covering Aurinia Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AUPH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $20 over the next 12 months.

How has AUPH stock performed over the past year?

Aurinia Pharmaceuticals, Inc. returned +26.4% over the 12 months to 13 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Aurinia Pharmaceuticals, Inc. do?

Aurinia Pharmaceuticals sells LUPKYNIS (voclosporin), the first FDA-approved oral therapy for active lupus nephritis, a serious kidney complication of lupus. The Edmonton, Canada-based biotechnology company, founded in 1993 and staffed by 128 people, also advances aritinercept, an experimental dual inhibitor of BAFF and APRIL for autoimmune diseases, in collaboration with Otsuka Pharmaceutical.

What is the latest news on AUPH?

The most recent item we track (Seeking Alpha, 12 Aug 2026): "Aurinia Pharmaceuticals Doubles Down On Its Pipeline". Aurinia Pharmaceuticals is advancing its pipeline, running the phase 4 PRESERVE trial in lupus nephritis testing combinations containing its drug Lupkynis, and developing aritinercept across four potential indications. However, Lupkynis could face potential challenges to its market exclusivity in the near future, and the company provides little clarity on timelines for further aritinercept updates.

Company

About Aurinia Pharmaceuticals, Inc.

Aurinia Pharmaceuticals sells LUPKYNIS (voclosporin), the first FDA-approved oral therapy for active lupus nephritis, a serious kidney complication of lupus. The Edmonton, Canada-based biotechnology company, founded in 1993 and staffed by 128 people, also advances aritinercept, an experimental dual inhibitor of BAFF and APRIL for autoimmune diseases, in collaboration with Otsuka Pharmaceutical. Trailing twelve-month revenue through June 2026 was $311.5 million.

CEO Mr. Kevin C. Tang · 128 employees · Canada · https://www.auriniapharma.com